Market Intelligence, Clinical Progress, and High-Purity Reagents for Renal Cell Carcinoma and Ovarian Cancer ADC Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CDH6-targeted ADC and bispecific development. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CDH6 ECD-Fc Fusion Protein (EC1-EC5), HEK293 expressed, High purity (>95%), Endotoxin <1EU/ug, Sequence Verified. Native glycosylation preserved. | View CDH6 Products |
| Gene Delivery | CDH6 Lentivirus Premade Particles, full-length ORF for stable cell line construction, preserves native conformation. | View CDH6 Products |
| Benchmark Ab | Anti-CDH6 (Clinical Lead Sequence, e.g., Raludotatug) – recombinant positive control for assay calibration. | View CDH6 Products |
| Validator | CDH6 siRNA Set for knockdown verification and specificity controls. | View CDH6 Products |
| Related Target 1 | CDH1 (E-Cadherin) – epithelial counter-screen; critical for selectivity assessment and off-target toxicity. | View CDH1 Products |
| Related Target 2 | CDH2 (N-Cadherin) – neural/cardiac safety liability screening. | View CDH2 Products |
| Related Target 3 | CDH11 (OB-Cadherin) – mesenchymal context evaluation; homology comparison. | View CDH11 Products |
| Related Target 4 | CA9 (Carbonic Anhydrase IX) – established RCC biomarker and ADC target; combination therapy rationale. | View CA9 Products |
| Related Target 5 | FOLR1 (Folate Receptor Alpha) – synergistic target for ovarian cancer biomarker panels and bispecific logic. | View FOLR1 Products |
| Related Target 6 | NECTIN4 – validated ADC target in urothelial and renal indications; benchmark for payload delivery comparison. | View NECTIN4 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cadherin Family Selectivity (CDH1/CDH2/CDH6/CDH11) | Homology Panel: HEK293-expressed ECD-Fc proteins with Sequence Verified identity; >95% purity by SEC-HPLC; mass spec verification. |
| ADC Internalization & Trafficking | Full-length CDH6 Lentivirus for stable cell lines; native glycosylation pattern preserved for conformational antibody recognition; high-purity ECD-Fc for binding characterization. |
| Cross-species Toxicology (Cyno/Mouse) | Human/Cynomolgus/Mouse CDH6 ortholog proteins available; theoretical MW verified by mass spec. |
| Lack of Validated Positive Controls & Binding Assays | Clinical Benchmark Antibodies (Biosimilars/lead sequences) precisely sequence-verified for reliable SPR/BLI reference data. |
| Off-target Kidney Toxicity Specificity | High-purity ECD-Fc enables epitope mapping and competition binding assays vs. normal kidney epitopes. |
| False Positives in Cell Assays | Validated siRNA sets for target knockdown; eliminate false positives in binding assays. |
Live CDH6 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CDH6-targeted therapeutics is intensifying, with early-phase clinical programs validating its role as a differentiated antigen for renal cell carcinoma (RCC) and ovarian cancer. As a cell adhesion molecule with restricted expression in normal tissues but high prevalence in specific malignancies, CDH6 represents an ideal ADC target. The global pipeline is currently led by ADC-centric biotechs and major oncology pharma, with first-generation therapies reaching advanced phases driven by topoisomerase I inhibitor payloads. The next wave of R&D is targeting internalization efficiency optimization, bispecific ADC architectures, and selectivity engineering to minimize off-target toxicity related to other cadherin family members. High-fidelity in vitro screening is paramount to navigate the narrow therapeutic windows associated with off-target binding to classical cadherins.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Daiichi Sankyo, Novartis, Aspen Neuroscience, BioNTech, Seagen/Pfizer | Ovarian Cancer, Renal Cell Carcinoma | Internalization Assay (High-purity HEK293 ECD-Fc; Lentivirus-stable cells for trafficking) |
| Bispecific T-cell Engager / Bispecific | Various biotech pipelines | Solid Tumors | Heterodimer Validation (Cross-reactive Abs; selectivity panel vs CDH1/CDH2) |
| CAR-T / CAR-NK | Academic / Early Biotech | Metastatic RCC, Refractory Thyroid/Ovarian | Epitope Specificity (Truncation mutants to map distinct binding domains; Lentivirus transduction for target cell generation) |